PTGES3L: A Promising Drug Target / Biomarker (G100885848)

Target Name: PTGES3L

NCBI ID: G100885848

PTGES3L

PTGES3L: A Promising Drug Target / Biomarker

Proteostasis, the study of protein regulation and interactions, is a critical field in modern biology. Many diseases, including cancer, neurodegenerative disorders, and metabolic diseases, are caused by disruptions in protein homeostasis. One of the key proteins involved in this process is poly (D,L-Proline) N-Acetylammonium (PDMA) dimer, also known as PTGES3L. In this article, we will explore the potential of PTGES3L as a drug target and its potential as a biomarker for various diseases.

Structure and Function

PDMA dimer is a protein that consists of two subunits, referred to as alpha- and beta-subunits. The alpha-subunit consists of a single alpha-helic acid loop, while the beta-subunit consists of a single beta-helic acid loop. The two subunits are held together by a disulfide bond, and the protein has a calculated molecular mass of 18.1 kDa.

PDMA dimer functions as a chaperone, helping to regulate the activity of other proteins. It has been shown to interact with a wide range of proteins, including transcription factors, enzymes involved in DNA replication and metabolism, and proteins involved in cell signaling pathways. In addition, PDMA dimer has been shown to play a role in the regulation of protein homeostasis, helping to maintain the stability of protein levels in the cell.

As a drug target, PDMA dimer has great potential as a therapeutic agent for a variety of diseases. One of the main advantages of PDMA dimer is its ability to interact with a wide range of proteins, making it a promising target for drugs that target protein interactions. For example, PDMA dimer has been shown to interact with proteins involved in a variety of diseases, including cancer, neurodegenerative disorders, and metabolic diseases.

In addition to its potential as a therapeutic agent, PDMA dimer also has the potential as a biomarker for a variety of diseases. One of the main advantages of PDMA dimer is its stability, which allows it to be used as a protein that can be measured and detected in the body. This makes it a potential biomarker for a variety of diseases, including cancer, neurodegenerative disorders, and metabolic diseases.

PDMA dimer has been shown to be involved in the regulation of a wide range of proteins, including transcription factors, enzymes involved in DNA replication and metabolism, and proteins involved in cell signaling pathways. It has also been shown to play a role in the regulation of protein homeostasis, helping to maintain the stability of protein levels in the cell.

In addition to its potential as a therapeutic agent and biomarker, PDMA dimer has also been shown to have a variety of other functions. For example, it has been shown to play a role in the regulation of cell adhesion, helping to maintain the integrity of tissues and organs. It has also been shown to play a role in the regulation of inflammation, helping to control the response of the immune system to harmful substances.

Conclusion

PDMA dimer is a protein that has a variety of functions and has been shown to be involved in the regulation of a wide range of proteins. As a drug target, it has great potential as a therapeutic agent for a variety of diseases. In addition to its potential as a therapeutic agent, PDMA dimer also has the potential as a biomarker for a variety of diseases. Further research is needed to fully understand the functions of PDMA dimer and its potential as a drug and biomarker.

Protein Name: Prostaglandin E Synthase 3 Like

The "PTGES3L Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PTGES3L comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets